Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients with Clinically Evident Cardiovascular Disease.
Sponsored by AMGEN – 2016 to present. Dr. Richard Rothschild, Principal Investigator
“GOULD Registry” - Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia management (GOULD): A Registry of High Cardiovascular Risk Subjects in the United States.
Sponsored by AMGEN – 2016 to present. Dr. Richard Rothschild, Principal Investigator
“FOURIER Trial” – A Double-blind, Randomized, Placebo-controlled Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 Is Used With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease.
Sponsored by AMGEN – 2013 to present. Dr. Richard Rothschild, Principal Investigator & Dr. David Schmidt, Sub-Investigator
Aastrom/Vericel - An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM Dr. David Schmidt, Principal Investigator & Dr. Richard Rothschild, Sub-Investigator
“PreSERVE Study” – A Prospective Randomized Double Blind Placebo Controlled Phase II Trial of Intracoronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product in Patients with Acute Myocardial Infarction.
Sponsored by Amorcyte - 2012. Dr. Richard Rothschild, Principal Investigator & Dr. David Schmidt, Sub-Investigator
“Renew Study” – A Prospective, Randomized, Double-Blinded, Active-Control and Unblinded Standard of Care (SOC) Controlled Study to Determine the Efficacy and Safety of Targeted Intramyocardial Delivery of G-CSF Mobilized Autologous CD34+Cells for the Improvement on Total Exercise Time During Standardized Exercise Testing in Subjects with Refractory Angina Pectoris and Chronic Myocardial Ischemia (CMI).
Sponsored by Baxter Health Corporation – 2012. Dr. Richard Rothschild, Sub-Investigator & Dr. David Schmidt, Sub-Investigator
Teva/Mesoblast - Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure. Dr. Richard Rothschild, Principal Investigator & Dr. David Schmidt, Sub-Investigator
